Navigation Links
Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
Date:2/28/2012

G1, REG2 and REG3 

Regado's lead program, the anticoagulant system REG1, consists of two agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin) with the second being its complementary active control agent (anivamersen).  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin.  REG1, recently completing phase 2b (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 has completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing shortly and will be indicated for antiplatelet therapy such as in treating diabetic vasculopathies.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
2. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
3. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
5. Regado Biosciences Establishes Medical Advisory Board
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
8. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
9. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
10. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
11. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... 2014 Bipartisan passage this week by ... to stimulate development and commercialization of new technologies and ... leaders of SPIE, the international society for optics ... and Innovation (RAMI) Act, now moves to the full ... they are optimistic that it will win passage there ...
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... 10 Bioheart, Inc., (OTC Bulletin Board: BHRT) a company ... diagnose and treat heart failure and other cardiovascular diseases announced ... development has been invited to participate in the 2009 World ... , Ms. Comella will speak on the concurrent ...
... , , , ... , Current studies show that only four ... point of care. By 2019, the Congressional Budget Office (CBO) estimates ... to about 90 percent , EHRs will create ...
... ATLANTA and LONDON, Sept. 10 CryoLife ... device and cardiovascular tissue processing company, today announced the first clinical ... received CE mark approval in August 2009. BioFoam was used in ... to promote hemostasis (a complex process that stops bleeding) by sealing ...
Cached Biology Technology:Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 2Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 2Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 3Greenway Medical Technologies Plays Leading Role in Interoperability Demonstrations at Seventh Annual Public Health Information Network (PHIN) Conference 4CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5
(Date:9/19/2014)... Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: NXTD ... focused on the growing m-commerce market, updates the "Wocket in Your ... the lightweight and light middleweight weight classes, Vinny Pazienza ... announced that Game of Thrones actor Ciaran Hinds ... Children star Katey Sagal have been cast in ...
(Date:9/18/2014)... small, icy moon of Uranus, is one of the ... system. Despite its relatively small size, Miranda appears to ... in the formation of at least three remarkable and ... , These coronae are visible in Miranda,s southern hemisphere, ... Arden corona, the largest, has ridges and troughs with ...
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... A new type of protein discovered by Queen’s University researchers ... as those that cause food poisoning and typhoid. , ... YihE or RdoA ?a team of professors and students from ... up possibilities for new drug development. , “Our ...
... from the Virginia Commonwealth University Massey Cancer Center ... of Cancer Research's annual meeting suggesting the potential ... leukemia (CLL). , In this study, ... of translational research, interactions between bortezomib and romidepsin ...
... found astonishing evidence that the lifelong use of two ... by four years compared to people who are monolingual. ... literature examining how lifestyle factors such as physical activity, ... in later years of life. Cognitive reserve refers to ...
Cached Biology News:Protein discovery targets antibiotic-resistant bacteria 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 3
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Medium bottle for hybridization 250 x 35mm...
Request Info...
Biology Products: